☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Janssen Pharmaceuticals
Janssen’s Type II Variation for Carvykti (ciltacabtagene autoleucel; Cilta-cel) Receives CHMP’s Positive Opinion to Treat Multiple...
February 23, 2024
Load more...
Back to Home